Shanghai Henlius Biotech (HKG:2696) said its breast cander drug, FUTUONING, has been included in China's National Reimbursement Drug List, a Sunday Hong Kong bourse filing said.

Shares of the drugmaker were down over 2% in Monday afternoon trading.

The inclusion is for the indication of drug in combination with Fulvestrant for the treatment of adult patients with breast cancer who have experienced disease progression after prior endocrine therapy.

The new edition of the list will become effective on Jan. 1, 2026.